Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase NA 9Phase 1/2 6Phase 4 5Phase 3 3Phase 2/3 3Phase 1 3

Status

Completed 8Unknown 5Terminated 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 1Gastrointestinal 1Classical hematology 1

Conditions

Breast Neoplasms 54Carcinoma, Hepatocellular 40Neoplasms 38Polycystic Ovary Syndrome 27Colorectal Neoplasms 24Stomach Neoplasms 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Carcinoma, Non-Small-Cell Lung 16Prostatic Neoplasms 15Recurrence 13Pancreatic Neoplasms 13Lymphoma 13Liver Neoplasms 12Urinary Bladder Neoplasms 11Leukemia, Myeloid, Acute 11Esophageal Neoplasms 11Leiomyoma 10Colonic Neoplasms 10Pain 9Lung Neoplasms 9Multiple Myeloma 8Uterine Cervical Neoplasms 7Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 7Keratosis, Actinic 7Infertility 7Papillomavirus Infections 6Pain, Postoperative 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6

Interventions

Pemetrexed 2Drug Therapy 2iron isomaltoside 1000 1icotinib 1elemene 1aumolertinib 1aflutinib 1Gemcitabine 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 4 × Unknown × Adenocarcinoma × Clear all
NCT04401059 2023-12-27

SELECT-2

Hangzhou Normal University

Phase 4 Unknown
744 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT01665417 2017-02-08

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown
100 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT01927328 2016-10-28

IRON

Nottingham University Hospitals NHS Trust

Phase 4 Unknown
40 enrolled
Classical hematologyGastrointestinal

Adenocarcinoma, Anemia, Esophageal Neoplasms, Stomach Neoplasms

NCT02103257 2015-04-29

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown
192 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT02194556 2014-07-18

Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown
100 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡